List view / Grid view
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S...
15 July 2014 | By BioStrata
For those that couldn’t attend, here is a summary of some of the interesting insights shared at ELRIG’s recent Robotics and Automation 2014 Conference.
9 July 2014 | By Domainex
Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...
9 July 2014 | By Fraunhofer IME
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
3 July 2014 | By MRC Technology
Initiative brings together global expertise to share compound libraries and streamline drug discovery...
30 June 2014 | By Taiho Oncology
Taiho Oncology, Inc. announced detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug...
16 June 2014 | By Oxford Global
After the continued success of the European Drug Discovery Summit Series, Oxford Global are pleased to announce the first Drug Discovery USA Congress...
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
19 May 2014 | By PerkinElmer
The Opera Phenix™ delivers uncompromising speed and sensitivity, accelerating the understanding of disease and discovery of new and more effective treatment therapies...
19 May 2014 | By Eureka Conferences
Eureka Conferences is pleased to announce Drug Discovery & Therapy World Congress 2014, scheduled to be held from 16th - 19th June, 2014...
16 May 2014 | By Oxford Global Conferences
Registration is now closing for Oxford Global’s Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe...
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…
